Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients by Joel Rodríguez-Saldaña, Francisco Padilla-Padilla, Ernesto G. Cardona-Muñoz, Yulia Romero-Antonio, María Marcela Arguedas-Núñez, José G. Sander-Padilla, Alberto Martínez-Muñoz, Laura A. Lugo-Sánchez, Ileana C. Rodríguez-Vazquez, Jorge González-Canudas

“…Cardiovascular diseases are the leading cause of death worldwide. The combination of statins and cholesterol-absorption inhibitors promotes the decrease in risk factors, such as high concentrations of LDL (low-density lipoproteins). …”
Get full text

Prevalence and Mortality Rates of Acute Kidney Injury among Critically Ill Patients: A Retrospective Study by Randa I. Farah, Othman A. Alfuqaha, Ali R. Younes, Hasan A. Mahmoud, Alhareth M. Al-Jboor, Mohammad M. Karajeh, Mohammad Z. Al-Masadeh, Omar I. Murad, Nathir Obeidat

“…Prior utilization of statins before admission exhibited a significant association with reduced mortality rate (AOR: 0.42; 95% CI: 0.2–0.85; p=0.02). …”
Get full text

Targeting Caveolin‐1 in Multiple Myeloma Cells Enhances Chemotherapy and Natural Killer Cell‐Mediated Immunotherapy by Dewen Zhan, Zhimin Du, Shang Zhang, Juanru Huang, Jian Zhang, Hui Zhang, Zhongrui Liu, Eline Menu, Jinheng Wang

“…The observation that CAV1 inhibition modulated by 6‐mercaptopurine, daidzin, and statins enhances the efficacy of bortezomib in vitro and in vivo highlights the translational significance of these FDA‐approved drugs in improving MM outcomes. …”
Get full text

M2 Macrophages as a Potential Target for Antiatherosclerosis Treatment by Ying Bi, Jixiang Chen, Feng Hu, Jing Liu, Man Li, Lei Zhao

“…Optimal medical treatments for atherosclerotic risk factors with current antihypertensive and lipid-lowering drugs (for example, statins) are widely used in clinical practice. However, many patients with established disease still continue to have recurrent cardiovascular events in spite of treatment with a state-of-the-art therapy. …”
Get full text

Inhibiting de novo lipogenesis identifies a therapeutic vulnerability in therapy-resistant colorectal cancer by Eeshrita Jog, Ashwin Kumar Jainarayanan, Alessandro La Ferlita, Arnab Chakraborty, Afiya Dalwai, Showket Yahya, Anusha Shivashankar, Bhagya Shree Choudhary, Aakash Chandramouli, Mufaddal Kazi, Darshan Jain, Nileema Khapare, Akshaya B, Bushra K. Khan, Poonam Gera, Prachi Patil, Rahul Thorat, Nandini Verma, Lalit Sehgal, Avanish Saklani, Siddhesh S. Kamat, Sorab N. Dalal, Nazia Chaudhary

“…Blocking the conversion of free fatty acids into LDs by treatment with statins or inhibiting lipin1 expression disrupts lipid homeostasis, leading to lipotoxicity and ferroptotic cell death in both DTPs and patient-derived organoids (PDOs) in vitro. …”
Get full text

Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHAR... by Xandra García-González, Alberto M Borobia, Antonio J Carcas, Miriam Estébanez, Montserrat Carmona, Irene García García, Francisco Abad-Santos, Luis A López-Fernández, Esther Cubo, Iñaki Imaz-Iglesia, Alicia Marín-Candón, Miriam Saiz-Rodríguez, Irene Taladriz-Sender, Pedro Arias, Rocío Rosas-Alonso, Enrique Seco-Meseguer, Stefan Stewart, Elena Diago-Sempere, María del Mar García Saiz, Emilio J Laserna-Mendieta, Ana M Peiró, Magí Farré, Consuelo Rodriguez-Jimenez, Judith Sanabria-Cabrera, Lucia Pedrosa, Ignacio Bernardino, Javier Guiijarro-Eguinoa, Arturo Gómez López De Las Huertas, Susana Martín-López, Olga Hladun Alvaro, Vicente Arrate, Ana Fries, Daniel Rodriguez Díaz, Fernando Marqués García, Núria Alonso Pedrol, Modesto M Maestre Muñiz, Leticia Rodríguez Alcolado, Carlos Ortiz-Bautista, Angela Remesal-Doblado, María Isabel Lucena, Zaida Salmón González, Inmaculada Coca-Prieto

“…After inclusion in the trial and genotyping has been performed, subjects will be randomly allocated to experimental group (pharmacogenetic genotype-guided statin prescription) or standard-of-care statin prescription (as deemed by attending physician). …”
Get full text

15-Lipoxygenase-1 Is Involved in the Effects of Atorvastatin on Endothelial Dysfunction by Peng Zhang, Xin Xing, Chunxiao Hu, Hui Yu, Qian Dong, Guanglei Chang, Shu Qin, Jian Liu, Dongying Zhang

“…Statins exert pleiotropic effects on endothelial cells in addition to lowering cholesterol. 15-Lipoxygenase-1 (ALOX15) has been implicated in vascular inflammation and disease. …”
Get full text

Demographics and Clinical and Endoscopic Characteristics of Patients with Helicobacter pylori Infection and Gastroesophageal Reflux Disease: A Case-Control Study by Amir Mari, Naim Mahroum, Nicola Luigi Bragazzi, Mahran Shalaata, Tawfik Khoury, Abdulla Watad, Mahmud Mahamid

“…In multivariate regression analysis, age (OR 0.987, p<0.001), smoking status (OR 0.190, p<0.001), use of ASA/NSAIDs (OR 1.652, p=0.004), and use of statins (OR 0.499 (95%CI 0.295-0.846), p=0.010) were found significant among H. pylori-positive individuals. …”
Get full text

Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study by Morten Lindhardt, Søren Tang Knudsen, Thomas Saxild, Morten Charles, Rikke Borg

“…ACEis/ARBs were prescribed to 65%, statins to 56%, SGTL2is to 14%, and MRAs to 8% of all individuals. …”
Get full text

Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review by Paul Little, Simon J Griffin, Hajira Dambha-Miller, Nazrul Islam, Ali Albasri, Christopher R Wilcox, Sam Hodgson, Shareen Khan

“…More studies reported upregulation than downregulation with ACE-I (n=22), ARBs (n=55), insulin (n=8), thiazolidinedione (n=7) aldosterone agonists (n=3), statins (n=5), oestrogens (n=5) calcium channel blockers (n=3) glucagon-like peptide 1 (GLP-1) agonists (n=2) and Non-steroidal anti-inflammatory drugs (NSAIDs) (n=2).Conclusions There is an abundance of the academic literature and media reports on the potential of drugs that could attenuate or exacerbate COVID-19 disease. …”
Get full text

Secondary prevention of preeclampsia by Muhammad Ilham Aldika Akbar, Muhammad Ilham Aldika Akbar, Roudhona Rosaudyn, Khanisyah Erza Gumilar, Khanisyah Erza Gumilar, Renuka Shanmugalingam, Gustaaf Dekker, Gustaaf Dekker

“…Pravastatin and other statins have shown positive results in lowering preterm PE and improving outcomes for both the mother and baby. …”
Get full text

Reduction effect of oral pravastatin on the acute phase response to intravenous zoledronic acid: protocol for a real-world prospective, placebo-controlled trial by Qi Liu, Min Zhang, Liyuan Tao, Chunli Song, Haiyan Li, Gengyu Han, Runting Li, Dongwei Fan, Guohong Du, Dongyang Liu

“…As a clinically used hypolipidaemic drug, statins can inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase to block the pathway upstream of farnesyl pyrophosphate synthase. …”
Get full text

Drug-induced autoimmune-like hepatitis: A disproportionality analysis based on the FAERS database. by Wangyu Ye, Yuan Ding, Meng Li, Zhihua Tian, Shaoli Wang, Zhen Liu

“…Disproportionality analysis identified 50 drugs with strong associations to DI-ALH, with biologics, statins, antibiotics, and antiviral drugs representing the most common categories. …”
Get full text

First results of the EuroHeart program by András Jánosi, Zoltán Járai

“…At the time of discharge from the hospital, among the drugs important in secondary prevention, statin use was the most common (92.1%). The EuroHeart population leaving the hospital, aspirin, P2Y12 inhibitors and statins were administered with appropriate frequency (91.3%, 94.8%, 94.1%). …”
Get full text

Risk factors for moderate disturbance of consciousness in patients with unilateral chronic subdural hematoma by Adrian Liebert, Thomas Eibl, Thomas Bertsch, Hans-Herbert Steiner, Karl-Michael Schebesch, Leonard Ritter

“…History of ischemic stroke and intake of statins were more common in group 1 (p = 0.033, p = 0.04; resp.). …”
Get full text

Simvastatin Posttreatment Controls Inflammation and Improves Bacterial Clearance in Experimental Sepsis by Flora Magno de Jesus Oliveira, Cassiano Felippe Gonçalves-de-Albuquerque, Isabel Matos Medeiros de Moraes, Patrícia Alves Reis, Vinicius Novaes Rocha, Patrícia Torres Bozza, Adriana Ribeiro Silva, Hugo Caire de Castro Faria Neto

“…In previous study from our group, statin pretreatment avoided cognitive damage and neuroinflammation in sepsis survivors. …”
Get full text

Changes induced in mouse lipid metabolism by simultaneous impact of antisense oligonucleotide derivatives to <i>apoB</i>, <i>PCSK9</i>, and <i>apoCIII</i> mRNAs by S. I. Oshevski, Y. I. Ragino, E. V. Kashtanova, Y. V. Polonskaya, E. M. Stakhneva, V. P. Nikolin, N. A. Popova, N. A. Kolchanov, M. I. Voevoda

“…Development of new drugs able to decrease the level of “bad” cholesterol, in particular, based on antisense oligonucleotide derivatives (ASOs), remains relevant for the patients with familial hypercholesterolemia and/or intolerant to statins. The goal of the work was to assess the changes in the lipid metabolism caused by variants of joint impact of the ASOs targeted to the mRNAs of its key genes: apoB, PCSK9, and apoCIII. …”
Get full text

Atrial fibrillation in acute coronary syndrome: clinical and anamnestic features and effects on the course by V.І. Tseluyko, F.B. Salem, N.A. Lopina, I.V. Kuznetsov

“…In patients of the 2nd group thrombolysis was recorded more often than among patients of the 1st group (12.2 vs 10.8 %), moreover, among patients of the 2nd group, a more frequent intake of statins was recorded to patients of the 1st group (5 vs 1.5 %), as well as more frequent treatment with ACE inhibitors/ARBs (35 vs 24.6 %). …”
Get full text

Diagnostic features, management and prognosis of type 2 myocardial infarction compared to type 1 myocardial infarction: a systematic review and meta-analysis by Kyle White, Ian Scott, Mansey Kinarivala

“…Compared with T1MI, patients with T2MI were: more likely to have pre-existing chronic kidney disease (OR 1.87; 95% CI 1.53 to 2.28) and chronic heart failure (OR 2.35; 95% CI 1.82 to 3.03), less likely to present with typical cardiac symptoms of chest pain (OR 0.19; 95% CI 0.13 to 0.26) and more likely to present with dyspnoea (OR 2.64; 95% CI 1.86 to 3.74); more likely to demonstrate non-specific ST-T wave changes on ECG (OR 2.62; 95% CI 1.81 to 3.79) and less likely to show ST elevation (OR 0.22; 95% CI 0.17 to 0.28); less likely to undergo coronary angiography (OR 0.09; 95% CI 0.06 to 0.12) and percutaneous coronary intervention (OR 0.06; 95% CI 0.04 to 0.10) or receive cardioprotective medications, such as statins (OR 0.25; 95% CI 0.16 to 0.38) and beta-blockers (OR 0.45; 95% CI 0.33 to 0.63). …”
Get full text

Quantitative examination of video-recorded NHS Health Checks: comparison of the use of QRISK2 versus JBS3 cardiovascular risk calculators by Christopher J Gidlow, Sarah Grogan, Lisa Cowap, Elizabeth Cottrell, Ruth Chambers, Naomi J Ellis, Victoria A Riley, Diane Crone, David Clark-Carter

“…Patients were eligible for NHSHC based on national criteria (aged 40–74, no existing cardiovascular-related diagnoses, not taking statins). Recruitment was stratified by patients’ age, gender and ethnicity.Methods Video recordings of NHSHC were coded, second-by-second, to quantify who was speaking and what was being discussed. …”
Get full text